Abstract:Abstract Pediatric cancer patients are commonly profiled with gene-panel sequencing tests that yield few actionable results, in part due to the complex genomic alterations that define these malignancies. We hypothesized that integration of whole-genome (WGS) and RNA sequencing (RNAseq), would lead to a more comprehensive understanding of these diseases. Our study is uniquely focused on metastatic and relapsed disease, whereas previous studies focused on primary cases. We also prioritized longitudinal profiling, including with deep sequencing, to capture tumor evolution across primary and metastatic sites and to quantify the utility of resampling. We assembled a cohort of 219 high-risk pediatric oncology patients, including solid tumors, CNS tumors, leukemias/lymphomas, patients with relapsed/refractory disease (75), metastatic disease at diagnosis (7), rare diagnoses (17), prior cancer history, and estimated overall survival <50%. We characterized 286 samples with WGS (tumor ~60X; germline ~30X) and/or RNAseq (polyA selected, ≥20 million reads), including 95 samples taken from 44 patients at different time points (diagnosis, relapse, etc.). Variants, structural rearrangements, mutational signatures, and copy-number alterations were identified using WGS. RNAseq was used to profile gene expression outliers, gene fusions, and expression of variants. Integrated results were used to prioritize potentially actionable variants. For 20 patients (44 samples), we performed targeted deep sequencing of the DNA (~500X). RNAseq identified potentially druggable outlier gene expression and fusions, including 102 novel fusions where the 3’ gene is overexpressed. WGS identified aneuploidy, loss of heterozygosity and whole genome duplication across histotypes. Mutational burden and mutational signatures analyses identified profound effects from platinum drugs on tumor evolution, but treatment effects were not universal. Multiple sampling per patient uncovered drastic spatial and temporal differences in the genomes and transcriptomes of these tumors. Custom deep sequencing confirmed these findings, captured evolution missed by WGS, and furthered our understanding of the complex impacts of treatment on clonal evolution. Histotypes differed by whether actionability was higher for WGS or RNAseq alone, but in 66% of samples modality integration increased actionability. Integration also identified a subset of tumors that may be amenable to immunotherapy, but which lack canonical markers of response. Longitudinal analysis highlighted both the opportunities and risks of targeted therapy, with targetable variants gained and lost between timepoints. Our study shows that integrated multi-modality sequencing can elucidate novel insights into the biology of pediatric cancers and identify potential therapeutic targets not detected using gene-panel testing alone. Citation Format: Henry J. Martell, Avanthi T. Shah, Alex G. Lee, Stanley G. Leung, Soo-Jin Cho, María Pons Ventura, Ana Golla, Amanda E. Marinoff, Elizabeth P. Young, Bogdan Tanasa, Inge Behroozfard, Heng-Yi Liu, Aviv Spillinger, Michelle L. Turski, Nicole Elzie-Tuttle, Carlos Espinosa-Mendez, Arun Rangaswami, Tabitha M. Cooney, Cassie Kline, Anurag Agrawal, Jennifer Michlisch, Elliot Stieglitz, Mignon Loh, Amit J. Sabnis, Kieuhoa T. Vo, Sheri Spunt, Norman Lacayo, Holly C. Beal, Florette K. Hazard, Sophie Salama, David Haussler, Olena M. Vaske, Marcus R. Breese, E. Alejandro Sweet-Cordero. Integrative longitudinal genomic analysis of therapy-resistant and metastatic pediatric cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1759.

Long-read sequencing of an advanced cancer cohort resolves rearrangements, unravels haplotypes, and reveals methylation landscapes

Abstract 6218: Haplotype-resolved analysis of cancer genomes and epigenomes using Oxford Nanopore sequencing

Scalable Nanopore sequencing of human genomes provides a comprehensive view of haplotype-resolved variation and methylation

Abstract LB081: Concurrent characterization of somatic nucleotide mutations, 5mC, and 5hmC methylation in clinical research samples using a single nanopore sequencing assay

Abstract 3493: Read-level methylation pattern extraction for high-multiplex large-scale targeted NGS assay

Abstract 1509: Longitudinal profiling of high-risk pediatric malignancies using a multiomics approach

Abstract 2704: Resolving clone-and haplotype-specific copy number variation and DNA methylation in heterogeneous tumors with nanopore sequencing

Abstract 3437: Whole genome and transcriptome sequencing of a pan cancer cohort unearths novel therapeutic avenues

The Application of Long-Read Sequencing to Cancer

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

Abstract 2934: Somatic variant workflow with HiFi sequencing provides new insights in highly challenging cancer cases

Abstract 6085: Leveraging targeted epigenetic and genetic detection for cost-effective cancer classification

Characterization of the Rat Osteosarcoma Cell Line UMR-106 by Long-Read Technologies Identifies a Large Block of Amplified Genes Associated with Human Disease

Abstract 2936: Nanopore adaptive sampling detects nucleotide variants and improves large scale rearrangement characterization for diagnosis of cancer predisposition

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features

Abstract 1759: Integrative longitudinal genomic analysis of therapy-resistant and metastatic pediatric cancers

Assessing the efficacy of target adaptive sampling long-read sequencing through hereditary cancer patient genomes

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

Abstract 4289: Long-read, Assembly-Based Characterization of Rearranged Cancer Karyotypes

Germline And Somatic Variant Identification Using Bgiseq-500 And Hiseq X Ten Whole Genome Sequencing

Performance of somatic structural variant calling in lung cancer using Oxford Nanopore sequencing technology